Judge Rules Against Plavix Recall Based On Sanofi/Bristol’s Settlement Negotiations
This article was originally published in The Pink Sheet Daily
Executive Summary
Provisions included in a Plavix patent infringement settlement agreement between Sanofi-Aventis/Bristol-Myers Squibb and Apotex "foresaw the possibility that Apotex would launch a generic product and prohibited Sanofi from seeking injunctive relief for a specific period of time after the launch occurred," Manhattan Federal Judge Sidney Stein said in an Aug. 31 ruling, refusing to grant a recall of generic clopidogrel
You may also be interested in...
Generic Drug Sales Grew 22 Percent In 2006 Driven By Unbranded Zocor, Plavix
Sales of Teva's simvastatin were $911 million, and sales of Apotex's clopidogrel were $902 million, according to IMS Health data.
Generic Drug Sales Grew 22 Percent In 2006 Driven By Unbranded Zocor, Plavix
Sales of Teva's simvastatin were $911 million, and sales of Apotex's clopidogrel were $902 million, according to IMS Health data.
Sanofi/Bristol Plavix Patent Suit To Begin Against Apotex
With preliminary injunction rulings weighing in Sanofi/Bristol's favor, Apotex's defense will need to make a strong case that clopidogrel patents are invalid.